Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor

[Image: see text] Boceprevir (SCH 503034), 1, a novel HCV NS3 serine protease inhibitor discovered in our laboratories, is currently undergoing phase III clinical trials. Detailed investigations toward a second generation protease inhibitor culminated in the discovery of narlaprevir (SCH 900518), 37...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Arasappan, Ashok, Bennett, Frank, Bogen, Stephane L., Venkatraman, Srikanth, Blackman, Melissa, Chen, Kevin X., Hendrata, Siska, Huang, Yuhua, Huelgas, Regina M., Nair, Latha, Padilla, Angela I., Pan, Weidong, Pike, Russell, Pinto, Patrick, Ruan, Sumei, Sannigrahi, Mousumi, Velazquez, Francisco, Vibulbhan, Bancha, Wu, Wanli, Yang, Weiying, Saksena, Anil K., Girijavallabhan, Viyyoor, Shih, Neng-Yang, Kong, Jianshe, Meng, Tao, Jin, Yan, Wong, Jesse, McNamara, Paul, Prongay, Andrew, Madison, Vincent, Piwinski, John J., Cheng, Kuo-Chi, Morrison, Richard, Malcolm, Bruce, Tong, Xiao, Ralston, Robert, Njoroge, F. George
Format: Artigo
Idioma:Inglês
Publicat: American Chemical Society 2010
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4007962/
https://ncbi.nlm.nih.gov/pubmed/24900178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml9000276
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars